» Articles » PMID: 27932065

Rovalpituzumab Tesirine and DLL3: a New Challenge for Small-cell Lung Cancer

Overview
Journal Lancet Oncol
Specialty Oncology
Date 2016 Dec 10
PMID 27932065
Citations 8
Authors
Affiliations
Soon will be listed here.
Citing Articles

Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.

He J, Zeng X, Wang C, Wang E, Li Y MedComm (2020). 2024; 5(8):e671.

PMID: 39070179 PMC: 11283588. DOI: 10.1002/mco2.671.


Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.

Krytska K, Casey C, Pogoriler J, Martinez D, Rathi K, Farrel A Cancer Res Commun. 2022; 2(7):616-623.

PMID: 36381237 PMC: 9648412. DOI: 10.1158/2767-9764.crc-22-0137.


[Over-expression of human Notch ligand Delta-like 3 promotes proliferation of human gastric cancer cells ].

Hu B, Ye J, Qiu X, Lin Y, Wu D, Wen J Nan Fang Yi Ke Da Xue Xue Bao. 2020; 38(1):14-19.

PMID: 33177031 PMC: 6765614. DOI: 10.3969/j.issn.1673-4254.2018.01.03.


Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis.

Chen B, Li H, Liu C, Wang S, Zhang F, Zhang L World J Surg Oncol. 2020; 18(1):226.

PMID: 32847588 PMC: 7448456. DOI: 10.1186/s12957-020-02004-5.


Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate.

Lashari B, Vallatharasu Y, Kolandra L, Hamid M, Uprety D Drugs R D. 2018; 18(4):255-258.

PMID: 30232719 PMC: 6277321. DOI: 10.1007/s40268-018-0247-7.